A Phase I Pharmacokinetic Study in HIV-Positive Subjects of Oral Ganciclovir and Concomitant Antiretroviral Zidovudine and Didanosine

Inclusion Criteria Concurrent Medication: Required: * Concomitant AZT or ddI. Allowed: * Probenecid. * Aerosolized pentamidine. Patients must have: * Asymptomatic HIV infection. * CMV seropositivity or CMV culture positivity at present or at any time in the past. * No history of CMV disease (e.g., retinitis, colitis) or any other AIDS-defining illness. * Treatment with AZT or ddI for at least 1 month prior to study entry. Exclusion Criteria Co-existing Condition: Patients with the following symptoms and conditions are excluded: * Uncontrolled diarrhea (three or more loose stools/day). * Clinically significant gastrointestinal symptoms including persistent nausea or abdominal pain. * AZT patients only: * Deficiency in glucose-6-phosphate dehydrogenase. * ddI patients only: * Grade 2 or worse peripheral neuropathy. Concurrent Medication: Excluded: * Combination antiretroviral therapy. * G-CSF or GM-CSF. * Acyclovir. * Amphotericin B. * Amikacin. * Captopril. * Carbamazepine. * Cimetidine. * Cyclosporine. * Glutethimide. * Gentamicin. * Griseofulvin. * Ibuprofen. * Imipenem-Cilastatin. * Lithium. * Methicillin. * Methotrexate. * Naproxen. * Pentamidine (Pentam 300) (Aerosolized drug permitted). * Phenacetin. * Phenobarbital. * Phenytoin. * Piroxicam. * Ribavirin. * Rifampin. * Tobramycin. * Vidarabine. * Zalcitabine. * Other investigational drugs. Patients with the following prior conditions are excluded: * History of hypersensitivity to acyclovir or ganciclovir. * AZT patients only: * History of gout, uric acid, kidney stones, peptic ulcer or porphyria. * ddI patients only: * History of pancreatitis or alcoholism, or seizures within 6 months prior to study entry or prior need for anticonvulsant therapy. Prior Medication: Excluded: * Combination antiretroviral therapy within 1 month prior to study entry. Required: * AZT at 500 mg/day for at least 1 month prior to study entry (with 100 mg administered five times per day for at least 1 week prior to study entry). OR * ddI at recommended dose for at least 1 month prior to study entry (with 250 mg administered every 12 hours for at least 1 week prior to study entry). History of alcoholism (in ddI patients).